Orforglipron (Foundayo): The FDA-Approved Weight Loss Pill That's Changing Everything in 2026
If you've been following the weight loss drug space, one name is dominating headlines in 2026: orforglipron . Sold under the brand name Founday , this once-daily oral pill developed by Eli Lilly is the first GLP-1 receptor agonist for weight loss that can be taken at any time of day — with or without food or water restrictions. The FDA gave it the green light on April 1, 2026, and the buzz hasn't stopped since. Here's everything you need to know. What Is Orforglipron (Foundayo)? Orforglipron is a small-molecule, non-peptide GLP-1 (glucagon-like peptide-1) receptor agonist — a category of drug that mimics a natural hormone your body releases after eating. That hormone, GLP-1, plays a key role in regulating appetite, food intake, and digestion. By activating GLP-1 receptors, orforglipron helps suppress hunger, makes you feel fuller faster, and slows down how quickly your stomach empties — all of which can lead to significant, sustained weight loss. What sets orforglipron ...